𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tolerance and Antiviral Effects of High-Dose Interferon-α B/D in Patients with Chronic Hepatitis B

✍ Scribed by M. C. Rasch; H. Schellekens; C. M. M. Van Dijck; E. B. Haagsma; P. P. Michielsen; A.H.J.A.M. Van Buuren; H. Stotter; J. Van Hattum

Book ID
110376838
Publisher
Springer US
Year
1998
Tongue
English
Weight
135 KB
Volume
43
Category
Article
ISSN
0163-2116

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Interferon antibodies may negate the ant
Interferon antibodies may negate the antiviral effects of recombinant α-interferon treatment in patients with chronic hepatitis B virus infection
✍ Dr. Anna Suk-Fong Lok; Ching-Lung Lai; Elsie Kit-Yee Leung 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 508 KB

In a randomized controlled trial of recombinant a-2a interferon for chronic hepatitis B, interferon antibodies developed in 21 (39%) of 54 Chinese adults who received IFN. No correlation was observed between sex, age, pretreatment serum ALT level or liver histological findings and the development of

Recombinant human γ-interferon in patien
Recombinant human γ-interferon in patients with chronic active hepatitis B: Pharmacokinetics, tolerance and biological effects
✍ Patrick Marcellin; Marie-Anne Loriot; Nathalie Boyer; Michéle Martinot-Peignoux; 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 397 KB

Pharmacokinetics, tolerance and biological effects of human recombinant y-interferon were studied in 12 patients with chronic active hepatitis B. Serum concentrations of y-interferon were measured by radioimmunoassay in four patients after a subcutaneous injection of 10 million U (0.6 mg); the peak

Absence of hepatitis B virus precore mut
Absence of hepatitis B virus precore mutants in patients with chronic hepatitis B responding to interferon-α
✍ Jianye Xu; David Brown; Tim Harrison; Yue Lin; Geoffrey Dusheiko 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 614 KB

Precore defective HBV mutants may gradually prevail because of immune selection and explain spontaneous seroconversion from HBeAg to anti-HBe in HBV carriers. We have analyzed whether the presence of precore HBV mutants is a determinant of responsiveness to interferon-a therapy. Fifteen carriers (ni